

Richard W Joseph

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/527528/publications.pdf>

Version: 2024-02-01

89

papers

17,370

citations

87888

38

h-index

53230

85

g-index

91

all docs

91

docs citations

91

times ranked

22336

citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. <i>European Journal of Cancer</i> , 2021, 144, 182-191.	2.8	57
2	Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial. <i>PLoS ONE</i> , 2021, 16, e0248097.	2.5	5
3	Hospitalization and emergency department utilization in patients with advanced melanoma receiving pembrolizumab versus ipilimumab plus nivolumab in US academic centers. <i>Journal of Medical Economics</i> , 2020, 23, 132-138.	2.1	6
4	Health-related quality of life (QoL) in patients with advanced melanoma receiving immunotherapies in real-world clinical practice settings. <i>Quality of Life Research</i> , 2020, 29, 2651-2660.	3.1	17
5	Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations. <i>PLoS ONE</i> , 2020, 15, e0230306.	2.5	27
6	Title is missing!. , 2020, 15, e0230306.		0
7	Title is missing!. , 2020, 15, e0230306.		0
8	Title is missing!. , 2020, 15, e0230306.		0
9	Title is missing!. , 2020, 15, e0230306.		0
10	Desmoplastic melanoma: a brief review and the efficacy of immunotherapy. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 205-207.	2.4	13
11	Drug-associated vasculitis occurring after treatment with pembrolizumab. <i>Rheumatology</i> , 2019, 58, 1501-1503.	1.9	3
12	The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). , 2019, 7, 354.		182
13	Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. <i>Clinical Cancer Research</i> , 2018, 24, 4960-4967.	7.0	222
14	Sentinel lymph node biopsy in Merkel cell carcinoma: The Mayo Clinic experience of 150 patients. <i>Surgical Oncology</i> , 2018, 27, 11-17.	1.6	48
15	High response rate to PD-1 blockade in desmoplastic melanomas. <i>Nature</i> , 2018, 553, 347-350.	27.8	269
16	NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab±everolimus for metastatic melanoma. <i>Cancer</i> , 2018, 124, 537-545.	4.1	27
17	Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 1668-1674.	1.6	360
18	Factors associated with immunotherapy selection in patients with advanced melanoma. <i>Immunotherapy</i> , 2018, 10, 1361-1369.	2.0	2

#	ARTICLE	IF	CITATIONS
19	Association Between Programmed Death-Ligand 1 Expression and the Vascular Endothelial Growth Factor Pathway in Angiosarcoma. <i>Frontiers in Oncology</i> , 2018, 8, 71.	2.8	22
20	Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2018, 24, 5250-5260.	7.0	116
21	Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. <i>Nature Medicine</i> , 2018, 24, 749-757.	30.7	900
22	New-onset insulin-dependent diabetes due to nivolumab. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2018, 2018, .	0.5	14
23	Nivolumab in Renal Cell Carcinoma: Current Trends and Future Perspectives. <i>Journal of Kidney Cancer and VHL</i> , 2018, 5, 15-18.	1.0	20
24	Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. <i>European Journal of Cancer</i> , 2017, 75, 47-55.	2.8	145
25	Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 142-148.	1.6	16
26	Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma. <i>Cancer Immunology Research</i> , 2017, 5, 357-362.	3.4	40
27	Clear Cell Type A and B Molecular Subtypes in Metastatic Clear Cell Renal Cell Carcinoma: Tumor Heterogeneity and Aggressiveness. <i>European Urology</i> , 2017, 71, 979-985.	1.9	52
28	Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. <i>Lancet, The</i> , 2017, 389, 67-76.	13.7	1,728
29	Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program. <i>Journal of Immunotherapy</i> , 2017, 40, 334-340.	2.4	16
30	BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor. <i>BMC Urology</i> , 2017, 17, 19.	1.4	26
31	A Study of Combination Bicalutamide and Raloxifene for Patients With Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 196-202.e1.	1.9	9
32	The Feasibility and Safety of Surgery in Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Study. <i>Frontiers in Oncology</i> , 2017, 7, 121.	2.8	48
33	Comprehensive Genomic Profiling of a Rare Thyroid Follicular Dendritic Cell Sarcoma. <i>Rare Tumors</i> , 2017, 9, 50-53.	0.6	8
34	Utility of ipilimumab in melanoma patients who progress on anti-PD-1 therapy. <i>Melanoma Management</i> , 2017, 4, 143-145.	0.5	8
35	Multicenter Validation of Enhancer of Zeste Homolog 2 Expression as an Independent Prognostic Marker in Localized Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 3706-3713.	1.6	34
36	Treatment of in-transit and metastatic melanoma in two patients treated with ipilimumab and topical imiquimod. <i>Melanoma Research</i> , 2016, 26, 409-412.	1.2	20

#	ARTICLE	IF	CITATIONS
37	Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab. <i>Cancer Immunology Research</i> , 2016, 4, 569-573.	3.4	20
38	NCCN Guidelines Insights: Melanoma, Version 3.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 945-958.	4.9	76
39	Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma. , 2016, 4, 81.		79
40	Validation of Gene Expression Signatures to Identify Low-risk Clear-cell Renal Cell Carcinoma Patients at Higher Risk for Disease-related Death. <i>European Urology Focus</i> , 2016, 2, 608-615.	3.1	7
41	Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1600.	7.4	857
42	Programmed Death-Ligand 1 Expression and Response to the Anti-“Programmed Death 1 Antibody Pembrolizumab in Melanoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 4102-4109.	1.6	528
43	Patient-derived tumor xenograft models for melanoma drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2016, 11, 895-906.	5.0	20
44	Efficacy of immunotherapy for metastatic mucosal melanoma. <i>Immunotherapy</i> , 2016, 8, 843-845.	2.0	3
45	Detection of tumor-associated cells in cryopreserved peripheral blood mononuclear cell samples for retrospective analysis. <i>Journal of Translational Medicine</i> , 2016, 14, 198.	4.4	17
46	Correlation Between Molecular Subclassifications of Clear Cell Renal Cell Carcinoma and Targeted Therapy Response. <i>European Urology Focus</i> , 2016, 2, 204-209.	3.1	40
47	Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. <i>Lancet, The</i> , 2016, 387, 1909-1920.	13.7	3,077
48	Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. <i>Journal of Clinical Oncology</i> , 2016, 34, 1510-1517.	1.6	627
49	Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific death. <i>Modern Pathology</i> , 2016, 29, 34-42.	5.5	55
50	Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression. <i>Journal of Urology</i> , 2016, 195, 180-187.	0.4	113
51	High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma. <i>Oncogene</i> , 2016, 35, 1565-1574.	5.9	72
52	Management of Metastatic Apocrine Hidradenocarcinoma with Chemotherapy and Radiation. <i>Rare Tumors</i> , 2015, 7, 133-135.	0.6	22
53	A Multidisciplinary Biospecimen Bank of Renal Cell Carcinomas Compatible with Discovery Platforms at Mayo Clinic, Scottsdale, Arizona. <i>PLoS ONE</i> , 2015, 10, e0132831.	2.5	9
54	Lichenoid Dermatitis in Three Patients with Metastatic Melanoma Treated with Anti-“PD-1 Therapy. <i>Cancer Immunology Research</i> , 2015, 3, 18-22.	3.4	100

#	ARTICLE	IF	CITATIONS
55	Whole Exome Sequencing of a Patient with Metastatic Hidradenocarcinoma and Review of the Literature. <i>Rare Tumors</i> , 2015, 7, 29-33.	0.6	11
56	Negative Sentinel Lymph Node Biopsy in Merkel Cell Carcinoma is Associated with a Low Risk of Same-Nodal-Basin Recurrences. <i>Annals of Surgical Oncology</i> , 2015, 22, 4060-4066.	1.5	39
57	Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy. <i>Molecular Immunology</i> , 2015, 67, 4-17.	2.2	180
58	Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non-V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1962-1971.	4.1	25
59	PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation. <i>Cancer Immunology Research</i> , 2015, 3, 1303-1307.	3.4	135
60	Follicular Dendritic Cell Sarcoma Presenting As a Thyroid Mass. <i>Journal of Clinical Oncology</i> , 2015, 33, e74-e76.	1.6	20
61	Steroid hormone influence on melanomagenesis. <i>Molecular and Cellular Endocrinology</i> , 2015, 417, 94-102.	3.2	38
62	Loss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 23.e9-23.e14.	1.6	40
63	Assessing the clinical use of clear cell renal cell carcinoma molecular subtypes identified by RNA expression analysis1These authors contributed equally to the writing of this article.. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 68.e17-68.e23.	1.6	10
64	Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma. <i>Drug Design, Development and Therapy</i> , 2014, 8, 775.	4.3	32
65	c-MET expression in primary and liver metastases in uveal melanoma. <i>Melanoma Research</i> , 2014, 24, 617-620.	1.2	30
66	Somatic expression of ENRAGE is associated with obesity status among patients with clear cell renal cell carcinoma. <i>Carcinogenesis</i> , 2014, 35, 822-827.	2.8	18
67	Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. <i>Lancet, The</i> , 2014, 384, 1109-1117.	13.7	1,588
68	Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma. <i>Cancer</i> , 2014, 120, 1059-1067.	4.1	129
69	ANKS1B is a smoking-related molecular alteration in clear cell renal cell carcinoma. <i>BMC Urology</i> , 2014, 14, 14.	1.4	47
70	Higher Expression of Topoisomerase II Alpha Is an Independent Marker of Increased Risk of Cancer-specific Death in Patients with Clear Cell Renal Cell Carcinoma. <i>European Urology</i> , 2014, 66, 929-935.	1.9	29
71	Evaluation of the association of prostate cancer-specific anxiety with sexual function, depression and cancer aggressiveness in men 1â€%year following surgical treatment for localized prostate cancer. <i>Psycho-Oncology</i> , 2013, 22, 1328-1335.	2.3	42
72	Age-period-cohort Analysis of Renal Cell Carcinoma in United States Adults. <i>Urology</i> , 2013, 82, 43-47.	1.0	25

#	ARTICLE	IF	CITATIONS
73	Severe Cutaneous and Neurologic Toxicity in Melanoma Patients during Vemurafenib Administration Following Anti-PD-1 Therapy. <i>Cancer Immunology Research</i> , 2013, 1, 373-377.	3.4	100
74	Ultrathin primary is a marker for worse prognosis in lymph node–positive cutaneous melanoma. <i>Cancer</i> , 2013, 119, 1860-1867.	4.1	7
75	Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma. <i>New England Journal of Medicine</i> , 2013, 369, 134-144.	27.0	3,128
76	Inverse Association between Programmed Death Ligand 1 and Genes in the VEGF Pathway in Primary Clear Cell Renal Cell Carcinoma. <i>Cancer Immunology Research</i> , 2013, 1, 378-385.	3.4	37
77	Obese men have more advanced and more aggressive prostate cancer at time of surgery than non-obese men after adjusting for screening PSA level and age: results from two independent nested case–control studies. <i>Prostate Cancer and Prostatic Diseases</i> , 2013, 16, 352-356.	3.9	33
78	An Integrated Model of the Transcriptome of HER2-Positive Breast Cancer. <i>PLoS ONE</i> , 2013, 8, e79298.	2.5	18
79	A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma. <i>Melanoma Research</i> , 2012, 22, 294-301.	1.2	53
80	Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma. <i>Clinical Cancer Research</i> , 2012, 18, 5329-5340.	7.0	266
81	Correlation of NRAS Mutations With Clinical Response to High-dose IL-2 in Patients With Advanced Melanoma. <i>Journal of Immunotherapy</i> , 2012, 35, 66-72.	2.4	111
82	Characterizing the Clinical Benefit of Ipilimumab in Patients Who Progressed on High-dose IL-2. <i>Journal of Immunotherapy</i> , 2012, 35, 711-715.	2.4	24
83	Vitamin D receptor upregulation in alloreactive human T cells. <i>Human Immunology</i> , 2012, 73, 693-698.	2.4	33
84	NRAS mutation status is an independent prognostic factor in metastatic melanoma. <i>Cancer</i> , 2012, 118, 4014-4023.	4.1	589
85	Therapy for metastatic melanoma: the past, present, and future. <i>BMC Medicine</i> , 2012, 10, 23.	5.5	179
86	High incidence of vitamin D deficiency in patients undergoing allogeneic stem cell transplantation. <i>American Journal of Hematology</i> , 2011, 86, 954-956.	4.1	26
87	Impact of Clinical and Pathologic Features on Tumor-Infiltrating Lymphocyte Expansion from Surgically Excised Melanoma Metastases for Adoptive T-cell Therapy. <i>Clinical Cancer Research</i> , 2011, 17, 4882-4891.	7.0	48
88	Chronic graft-versus-host disease after allogeneic stem cell transplantation: challenges in prevention, science, and supportive care. <i>The Journal of Supportive Oncology</i> , 2008, 6, 361-72.	2.3	9
89	Three Hundred Consecutive Emergent Celiotomies in General Surgery Patients. <i>Annals of Surgery</i> , 2002, 235, 681-689.	4.2	24